The research of transcription factor CEBPB activates FJX1 to promote the proliferation,invasion,migration and angiogenesis of colon cancer cells
10.3969/j.issn.1673-9701.2024.03.009
- VernacularTitle:转录因子CEBPB激活FJX1促进结肠癌细胞的增殖、侵袭、迁移和血管生成能力的研究
- Author:
Xianglong TENG
1
,
2
;
Xiyuan ZHU
1
,
2
;
Wujun ZOU
1
,
2
Author Information
1. Department of Anorectal Surgery, Lishui People&rsquo
2. s Hospital, Lishui 323000, Zhejiang, China
- Publication Type:Journal Article
- Keywords:
Colon cancer;
CEBPB;
FJX1;
Angiogenesis;
Cell proliferation
- From:
China Modern Doctor
2024;62(3):35-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the regulatory relationship between CCAAT enhancer binding protein beta(CEBPB)and four-jointed box kinase 1(FJX1)in colon cancer and their effect on colon cancer(CC)malignant progression and angiogenesis.Methods Bioinformatics was used to analyze the expression of FJX1 and CEBPB in CC and the regulatory relationship between them.Real-time quantitative reverse transcription polymerase chain reaction(qRT-PCR)was used to verify the expression of FJX1 and CEBPB in CC cells,and chromatin immunoprecipitation(CHIP)and dual luciferase assay were used to verify the binding relationship between FJX1 and CEBPB.The effects of FJX1 and CEBPB on the viability,migration,invasion and angiogenesis of CC cells were detected by cell counting kit-8(CCK-8),scratch test,Transwell and angiogenesis test.Results This study revealed that FJX1 was highly expressed in CC.Inhibiting the expression of FJX1 could significantly inhibit the cell viability,migration,invasion and angiogenesis of CC cells.Subsequently,we found that CEBPB was an upstream regulatory gene of FJX1,and CEBPB was highly expressed in CC.CHIP and dual luciferase experiments showed that CEBPB could bind to FJX1.The results of cell experiments showed that the transcription factor CEBPB could promote the proliferation,migration,invasion and angiogenesis of CC cells by activating FJX1.Conclusion CEBPB/FJX1 axis played a cancer-promoting role in the progression of CC,suggesting that CEBPB and FJX1 may be potential therapeutic targets for CC.
